Flotillin 2 Antibody [A21G15] | Primary Antibodies

Application: Reactivity: Human

Usage Information

Dilution
WB1:1000-1:10000 IP1:40

Application
WB, IP

Reactivity
Human

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
27 kDa,47 kDa 27 kDa,47 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight.

Positive Control	HEK293T cells; HeLa cells; A549 cells; 293 cells; A375 cells
Negative Control

Datasheet & SDS

Biological Description

Specificity
Flotillin 2 Antibody [A21G15] detects endogenous levels of total Flotillin 2 protein.

Clone
A21G15

Synonym(s)
ESA1; M17S1; FLOT2; Flotillin-2; Epidermal surface antigen; Membrane component chromosome 17 surface marker 1; ESA.

Background
Flotillin-2 (FLOT2) is a member of the flotillin/band 7/stomatin protein family, serving as an integral membrane scaffold protein that self-organizes into lipid raft microdomains on the plasma membrane and endosomal compartments, where its N-terminal transmembrane domain and central flotillin domain containing conserved stomatin homology mediate hetero-oligomerization with flotillin-1 to form stable caveolin-independent lipid platforms critical for organizing signal transduction. FLOT2 (approximately 428 amino acids) features an N-terminal hydrophobic anchor, a central SPFH domain (residues ~70-140) for oligomerization, and a C-terminal charged region for cytoskeletal coupling, creating rigidified membrane curvatures that recruit signaling complexes in the absence of caveolin. FLOT2 orchestrates receptor endocytosis and trafficking by internalizing EGFR, IGFR, and receptor tyrosine kinases via clathrin-independent pathways, coordinates MAPK/ERK signaling through Ras nano-clustering to drive proliferation, modulates Wnt/β-catenin signaling via Dishevelled recruitment affecting stemness and differentiation, and regulates actin remodeling through flotillin-actin linker proteins to control lamellipodia formation and migration. FLOT2 maintains membrane proteome homeostasis and polarized trafficking in neurons and muscle, while pathologically, its upregulation drives EGFR-addicted cancers such as non-small cell lung cancer and breast cancer via enhanced signaling and trafficking, is associated with Alzheimer's disease through APP and tau compartmentalization, and links to metabolic syndrome via insulin receptor desensitization.

Background

Flotillin-2 (FLOT2) is a member of the flotillin/band 7/stomatin protein family, serving as an integral membrane scaffold protein that self-organizes into lipid raft microdomains on the plasma membrane and endosomal compartments, where its N-terminal transmembrane domain and central flotillin domain containing conserved stomatin homology mediate hetero-oligomerization with flotillin-1 to form stable caveolin-independent lipid platforms critical for organizing signal transduction. FLOT2 (approximately 428 amino acids) features an N-terminal hydrophobic anchor, a central SPFH domain (residues ~70-140) for oligomerization, and a C-terminal charged region for cytoskeletal coupling, creating rigidified membrane curvatures that recruit signaling complexes in the absence of caveolin. FLOT2 orchestrates receptor endocytosis and trafficking by internalizing EGFR, IGFR, and receptor tyrosine kinases via clathrin-independent pathways, coordinates MAPK/ERK signaling through Ras nano-clustering to drive proliferation, modulates Wnt/β-catenin signaling via Dishevelled recruitment affecting stemness and differentiation, and regulates actin remodeling through flotillin-actin linker proteins to control lamellipodia formation and migration. FLOT2 maintains membrane proteome homeostasis and polarized trafficking in neurons and muscle, while pathologically, its upregulation drives EGFR-addicted cancers such as non-small cell lung cancer and breast cancer via enhanced signaling and trafficking, is associated with Alzheimer's disease through APP and tau compartmentalization, and links to metabolic syndrome via insulin receptor desensitization.

References
https://pubmed.ncbi.nlm.nih.gov/41663364/ https://pubmed.ncbi.nlm.nih.gov/11159550/

Reference Table for Selecting PVDF Membrane Pore Size Specifications

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%